Prescription opioid abuse and diversion are major causes of morbidity and mortality in the United States. The buprenorphine transdermal delivery system (BTDS) is indicated for the treatment of moderate to severe chronic pain and provides a continuous dose of 5, 7.5, 10, 15 or 20 micrograms per hour of buprenorphine for 7 days.Quarterly rates of abuse and diversion of BTDS were compared to four comparator groups: 1) other buprenorphine products, 2) fentanyl patches, 3) extended-release (ER) opioid tablets/capsules, and 4) ER tramadol.
from The Journal of Pain http://ift.tt/1RnMlQR
via IFTTT
No comments:
Post a Comment